DUBLIN--(BUSINESS WIRE)--The "Sarcopenia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" report has been added to ResearchAndMarkets.com's offering.
The study analyzed that the sarcopenia therapeutics pipeline comprises of 13 drug candidates in different stages of development. Further, the analysis also states that the pipeline has around 15% of the drug candidates that are being developed as gene therapy.
Novartis AG, and Regeneron Pharmaceuticals Inc., have one drug candidate each in the Phase II stage of development for the treatment of the disease. In December 2017, Biophytis SAS announced that the Federal Agency for Medicines and Health Products (FAMHP) approved to conduct the SARA-INT Phase II interventional study of sarcopenia in Belgium.
The drugs being developed by the various pharmaceutical companies for the treatment of sarcopenia have demonstrated positive clinical trial results which in-turn aids in their further development. For instance, In June 2017, Novartis AG announced the positive results of a 24-week randomized, double-blind, placebo-controlled, parallel-arm, proof-of-concept study of bimagrumab on skeletal muscle mass and function in older adults with sarcopenia and mobility limitations. In February 2016, ATA 842 demonstrated increased muscle mass and muscle strength in the treatment of young and old mice in four weeks.
It has been observed that most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of sarcopenia. For instance, in June 2016, Novartis AG received patent for the invention related to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of age-related sarcopenia (WO2015IB59369 20151204). Patent approval helps in increasing opportunities for invention improvement and uniqueness for the pharmaceutical companies.
- Novartis AG
- Biophytis SAS
- Vibe Pharmaceuticals LLC
Other Notable Players
- Neurotune AG
Key Topics Covered
1. Research Background
2. Research Methodology
3. Executive Summary
4. Pipeline Outlook
5. Sarcopenia Therapeutics Pipeline Analysis by Phase (2018)
6. Clinical Trials Review
7. Competitive Landscape
8. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/b255lb/sarcopenia?w=4